Amneal Pharmaceuticals, Inc. (AMRX)

USD 7.35

(2.3%)

Gross Profit Summary of Amneal Pharmaceuticals, Inc.

Amneal Pharmaceuticals, Inc.'s latest annual gross profit in 2023 was 820.56 Million USD , up 4.57% from previous year.
Amneal Pharmaceuticals, Inc.'s latest quarterly gross profit in 2024 Q1 was 238.06 Million USD , up 25.41% from previous quarter.
Amneal Pharmaceuticals, Inc. reported a annual gross profit of 784.7 Million USD in annual gross profit 2022, up 2.05% from previous year.
Amneal Pharmaceuticals, Inc. reported a annual gross profit of 768.97 Million USD in annual gross profit 2021, up 22.37% from previous year.
Amneal Pharmaceuticals, Inc. reported a quarterly gross profit of 249.94 Million USD for 2024 Q2, up 4.99% from previous quarter.
Amneal Pharmaceuticals, Inc. reported a quarterly gross profit of 820.56 Million USD for 2023 FY, up 4.57% from previous quarter.

Annual Gross Profit Chart of Amneal Pharmaceuticals, Inc. (2023 - 2014)

Historical Annual Gross Profit of Amneal Pharmaceuticals, Inc. (2023 - 2014)

Year	Gross Profit	Gross Profit Growth
2023	820.56 Million USD	4.57%
2022	784.7 Million USD	2.05%
2021	768.97 Million USD	22.37%
2020	628.39 Million USD	78.02%
2019	352.99 Million USD	-50.73%
2018	716.4 Million USD	36.15%
2017	526.17 Million USD	-11.93%
2016	597.45 Million USD	19.68%
2015	499.22 Million USD	11.03%
2014	449.63 Million USD	0.0%

Year	Gross Profit	Gross Profit Growth
2024 Q1	238.06 Million USD	25.41%
2024 Q2	249.94 Million USD	4.99%
2023 FY	820.56 Million USD	4.57%
2023 Q4	189.82 Million USD	-18.36%
2023 Q1	178.18 Million USD	-17.27%
2023 Q3	232.53 Million USD	5.69%
2023 Q2	220.02 Million USD	23.48%
2022 Q1	174.57 Million USD	4.91%
2022 FY	784.7 Million USD	2.05%
2022 Q4	215.38 Million USD	10.89%
2022 Q3	194.23 Million USD	-3.14%
2022 Q2	200.51 Million USD	14.86%
2021 Q3	198.51 Million USD	-6.58%
2021 Q4	166.4 Million USD	-16.17%
2021 Q2	212.49 Million USD	10.93%
2021 Q1	191.56 Million USD	14.66%
2021 FY	768.97 Million USD	22.37%
2020 Q2	144.23 Million USD	-21.4%
2020 Q4	167.07 Million USD	25.07%
2020 FY	628.39 Million USD	78.02%
2020 Q3	133.58 Million USD	-7.39%
2020 Q1	183.49 Million USD	66.46%
2019 Q2	105.24 Million USD	26.68%
2019 Q4	110.23 Million USD	102.51%
2019 FY	352.99 Million USD	-50.73%
2019 Q1	83.08 Million USD	-57.04%
2019 Q3	54.43 Million USD	-48.28%
2018 Q2	178.29 Million USD	23.31%
2018 FY	716.4 Million USD	36.15%
2018 Q4	193.4 Million USD	-3.35%
2018 Q3	200.1 Million USD	12.23%
2018 Q1	144.59 Million USD	-4.5%
2017 FY	526.17 Million USD	-11.93%
2017 Q1	109.84 Million USD	-37.82%
2017 Q2	123.73 Million USD	12.64%
2017 Q3	135.01 Million USD	9.12%
2017 Q4	151.41 Million USD	12.15%
2016 Q4	176.65 Million USD	0.0%
2016 FY	597.45 Million USD	19.68%
2015 FY	499.22 Million USD	11.03%
2014 FY	449.63 Million USD	0.0%

Peer Gross Profit Comparison of Amneal Pharmaceuticals, Inc.

Name	Gross Profit	Gross Profit Difference
Bausch Health Companies Inc.	6.19 Billion USD	86.761%
Catalent, Inc.	953 Million USD	13.897%
Emergent BioSolutions Inc.	343.9 Million USD	-138.606%
Elanco Animal Health Incorporated	2.48 Billion USD	66.993%
Perrigo Company plc	1.68 Billion USD	51.168%
Teva Pharmaceutical Industries Limited	7.64 Billion USD	89.268%
Zoetis Inc.	5.83 Billion USD	85.935%